This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): N1, N11-Diethylnorspermine
Description: DENSPM is related to the spermine analogue DESpm. Spermine is a polyamine involved in cellular metabolism. While the exact function of polyamines is unclear, if their synthesis is inhibited, cell growth is stopped or severely retarded. This system is highly active in rapidly proliferating cells, and are essential for initiating and sustaining tumor growth.
By suppressing natural polyamine biosynthesis and turning on catabolism, DENSPM achieves rapid polyamine depletion. The net result is the elimination of natural polyamine pools and their replacement with an analog incapable of substituting for polyamines in growth-related functions.
Polyamine analogues decrease the biosynthesis of polyamines by down-regulating ODC5 and S-adenosylmethionine decarboxylase (AdoMetDC), key biosynthetic enzymes in the polyamine pathway. Catabolism is increased by the induction of the enzyme spermidine/spermine N1-acetylatransferase (SSAT) and in some cases inducting polyamine oxidase.
Deal Structure: In October 2010, Sanofi-aventis announced it has commenced a tender offer for all outstanding shares of common stock of Genzyme for $69 per share, net to the seller in cash, without interest and less any required withholding taxes. In April 2011, Sanofi-aventis announced that it successfully completed its exchange offer for all outstanding shares of common stock of Genzyme Corporation.
Pink Sheet Warner-Lambert
Additional information available to subscribers only: